Physician profile
David John Olek
NPI 1821431370
$937.08
in general payments reported to CMS, 2019-2025
25 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $57.43 · 2021: $35.90 · 2022: $253 · 2023: $107 · 2024: $166 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426 · Education: $44.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.61 |
| Education | $44.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $153.73 | 2019-2025 | Optune Gio |
| Mim Software INC. | $76.00 | 2024 | Maestro |
| Siemens Medical Solutions USA, INC. | $73.20 | 2022-2025 | Truebeam, Eclipse Treatment Planning System For External Beam Radiation Therapy |
| Genmab U.S., INC. | $64.71 | 2025 | Epkinly |
| Novartis Pharmaceuticals Corporation | $48.26 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $46.99 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $44.93 | 2024 | Orgovyx |
| Myriad Genetic Laboratories, INC. | $38.76 | 2023 | Myrisk, Precisetumor |
| Daiichi Sankyo INC. | $37.91 | 2020-2023 | Enhertu |
| Fortovia Therapeutics, INC. | $37.80 | 2019 | |
| Alexion Pharmaceuticals, INC. | $33.57 | 2022 | |
| Boston Scientific Corporation | $32.15 | 2019-2020 | |
| Amgen INC. | $27.77 | 2022 | |
| Progenics Pharmaceuticals, INC. | $24.19 | 2025 | |
| Myovant Sciences INC. | $23.93 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.87 | 2024 | Jaypirca |
| Morphosys, US INC. | $21.21 | 2024 | Monjuvi |
| Genentech USA, INC. | $18.45 | 2025 | Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $17.77 | 2020 | |
| Global Blood Therapeutics, INC. | $16.12 | 2022 | |
| Puma Biotechnology, INC. | $16.07 | 2019 | |
| Varian Medical Systems, INC. | $15.88 | 2019 | |
| Kyowa Kirin, INC. | $15.74 | 2022 | |
| G1 Therapeutics, INC. | $14.70 | 2022 | |
| Seagen INC. | $13.37 | 2023 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Olek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.